Wilmer Eye Institute, Johns Hopkins University School of Medicine, Baltimore, Maryland, United States.
Kasr Al Ainy School of Medicine, Cairo University, Cairo, Egypt.
Invest Ophthalmol Vis Sci. 2019 Aug 1;60(10):3422-3431. doi: 10.1167/iovs.19-27151.
The degenerative corneal disease keratoconus is a leading indicator for corneal transplant with an unknown etiology. We recently identified the activation of the integrated stress response (ISR) in ex vivo human corneas and in vitro cell culture. Utilizing small molecules to modulate the ISR we sought to investigate the effects of stimulating the ISR in healthy cells to recapitulate aspects of the in vitro keratoconic phenotype and whether relieving the ISR signaling would recover the disease phenotype.
Corneal fibroblasts were extracted from patients undergoing corneal transplant or unaffected cadaverous donor limbal rings. Cells were exposed to the DNA damage-inducible protein (GADD34) inhibitor SAL003 to stimulate the ISR, or Trans-ISRIB to relieve ISR signaling pathway. Collagen production was assessed through hydroxyproline production, Sirius Red incorporation, or quantitative (q)PCR. Western blotting, hydroxyproline, and qPCR were used to assess components of the ISR pathway and collagen production.
ISR stimulation through SAL003 resulted in significant decrease of hydroxyproline and COL1A1 transcription and eventual apoptosis in normal fibroblasts. Patient (KC) fibroblast production of hydroxyproline was increased in response to ISRIB, while matrix metalloproteinase (MMP)9 production was lowered. The prospective biomarker of keratoconus prolactin-inducible factor was also upregulated in KC fibroblast cultures in response to ISRIB. Inflammatory markers TNFα and IL-1β were unaffected.
Activation of the ISR is sufficient to recapitulate many key aspects of the KC phenotype in unaffected cells in vitro. Inhibition of the ISR also relieves many of the hallmarks of KC in affected cells. Therefore, targeting of the ISR through small molecules is a potential therapeutic path for small molecule treatment of keratoconus.
退行性角膜疾病圆锥角膜是角膜移植的主要指征,其病因不明。我们最近在离体人角膜和体外细胞培养中发现了整合应激反应(ISR)的激活。利用小分子来调节 ISR,我们试图研究在健康细胞中刺激 ISR 以重现体外圆锥角膜表型的某些方面,以及缓解 ISR 信号是否会恢复疾病表型。
从接受角膜移植或未受影响的尸体供体角膜缘环的患者中提取角膜成纤维细胞。将细胞暴露于 DNA 损伤诱导蛋白(GADD34)抑制剂 SAL003 以刺激 ISR,或 Trans-ISRIB 以缓解 ISR 信号通路。通过羟脯氨酸产量、Sirius Red 掺入或定量(q)PCR 评估胶原产生。使用 Western blot、羟脯氨酸和 qPCR 来评估 ISR 途径和胶原产生的成分。
通过 SAL003 刺激 ISR 导致正常成纤维细胞中羟脯氨酸和 COL1A1 转录的显著减少,并最终导致细胞凋亡。ISRIB 响应时,患者(KC)成纤维细胞羟脯氨酸的产生增加,而基质金属蛋白酶(MMP)9 的产生降低。在 KC 成纤维细胞培养物中,也上调了潜在的圆锥角膜生物标志物催乳素诱导因子。炎症标志物 TNFα 和 IL-1β 不受影响。
ISR 的激活足以在体外未受影响的细胞中重现 KC 表型的许多关键方面。ISR 的抑制也缓解了受影响细胞中 KC 的许多特征。因此,通过小分子靶向 ISR 是治疗圆锥角膜的小分子治疗的潜在治疗途径。